Ep. 261, Chapter 2: Epic Bio's Fundraising Philosophy With Amber Salzman, Ph.D.

8:05 – 12:11

Salzman explains how the company was able to secure $68 million in a Series B funding round despite a challenging market for early-stage companies. First, Epic Bio focused on patient needs. Beyond simply offering a promising platform, the company worked hard toward developing preclinical data for specific applications to address pressing patient needs.

Next, the company strove to be efficient in the use of its capital, demonstrating to investors its ability to advance transformational medicines quickly and safely. Finally, Epic Bio carefully targeted potential investors. Salzman emphasized that it is important to leverage relationships with past investors as well as "kiss a lot of frogs" in the current environment—pitching to numerous investors to find those willing to back a new modality based on strong data.